- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
|Dr Hector Peinado Selgas using his NanoSight LM-10 system at Weill Cornell Medical College, New York|
NanoSight, leading manufacturers of unique nanoparticle characterization technology, reports on the breakthrough cancer metastasis research of Dr. Hector Peinado Selgas and Dr. David Lyden's research team from Weill Cornell Medical College.
Lead study author Dr. Peinado, Instructor of Molecular Biology in the Department of Pediatrics at Weill Cornell, describes in his recent published research work in Nature Medicine* with senior author Dr. Lyden's research group how they were able to gain better understanding and characterization of exosomes, secreted nanoparticles from tumor cells.
"In our laboratory, we are interested in analyzing the role of tumor-secreted exosomes in metastasis. We have recently published a study describing how exosomes secreted from melanoma tumor cells are educating bone marrow derived progenitor cells toward a pro-metastatic phenotype. We are also interested in analyzing the use of exosomes as biomarkers of specific tumor types and their use as prognostic factors, on which Cornell University currently has pending patents on this technology."
"We have found that the protein content per exosome is increased in metastatic melanoma patients. In addition, we have observed that metastatic cell lines also have increased protein content per exosome. Therefore, knowing the number of exosomes was a definitive and necessary step in our reseach. Before this work, we were only following qualitative changes in exosomes. Now we are able to make quantitative analyses using Nanoparticle Tracking Analysis technology. This has faciliated our recent research work."
"Prior to using NTA, I was measuring exosome size by electron microscopy. There was no other technique available. The new technology allows us to analyze millions of particles, particle by particle, in minutes giving not only numbers but also population distribution. Although the measurement of the size of the particles is not as accurate as the electron microscopy, NTA does allow us to process a large number of samples in a short time period."
To find out more about NanoSight and to learn about particle characterization using the company's unique nanoparticle tracking analysis instruments, visit www.nanosight.com and register to receive the next issue of NanoTrail, the company's electronic newsletter.
* "Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET"
Nature Medicine18, 883-891 (2012) doi:10.1038/nm.2753
NanoSight delivers the world's most versatile and proven multi-parameter nanoparticle analysis in a single instrument.
NanoSight's "Nanoparticle Tracking Analysis" (NTA) detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Additionally, NanoSight measures concentration and a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. Zeta potential measurements are similarly particle-specific. It is this particle-by-particle methodology that takes NTA beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions and validates data with information-rich video files of the particles moving under Brownian motion.
This simultaneous multiparameter characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, and in nanotoxicology. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner. NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles.
NanoSight has installed more than 500 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. NanoSight's technology is validated by 500+ third party papers citing NanoSight results. NanoSight’s leadership position in nanoparticle characterization is consolidated further with publication of an ASTM International standard, ASTM E2834, which describes the NTA methodology for detection and analysis of nanoparticles.
For more information, please click here
Amesbury SP4 7RT UK
T +44(0)1980 676060
F +44(0)1980 624703
Talking Science Limited
39 de Bohun Court
Essex CB10 2BA UK
T +44(0)1799 521881
M +44(0)7843 012997
Copyright © NanoSightIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Controlled electron pulses November 30th, 2016